Cautious Hold Rating for Enhabit Amid Court Ruling and Acquisition Uncertainties
Enhabit Analyst Ratings
Jefferies Upgrades Enhabit to Buy, Raises Price Target to $9.5
Jefferies Upgrades Enhabit(EHAB.US) to Buy Rating, Raises Target Price to $9.5
Enhabit, Inc.: Operational Stability Amid Growth Challenges Leads to Hold Rating
Enhabit Analyst Ratings
Leerink Partners Reiterates Market Perform on Enhabit, Lowers Price Target to $8
Oppenheimer Keeps Their Hold Rating on Enhabit, Inc (EHAB)
TD Cowen Maintains Enhabit(EHAB.US) With Hold Rating, Maintains Target Price $8
Enhabit, Inc.: Mixed Q3 Results and Lowered 2024 Guidance Justify Hold Rating
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)
TD Cowen Maintains Enhabit(EHAB.US) With Hold Rating, Maintains Target Price $8
Maintaining Hold on Enhabit, Inc.: Weighing Operational Gains Against Rate Headwinds and Strategic Risks
TD Cowen Sticks to Their Hold Rating for Enhabit, Inc (EHAB)
Enhabit Analyst Ratings
Enhabit Analyst Ratings
Hold Rating on Enhabit, Inc. Maintained Amid EBITDA Beat and Ongoing Uncertainties
Leerink Partners Sticks to Its Sell Rating for Enhabit, Inc (EHAB)
Enhabit Analyst Ratings
Enhabit, Inc (EHAB) Receives a Rating Update From a Top Analyst